HB86 Summary

• Prohibits state-regulated health benefit plans from charging higher copayments, deductibles, or coinsurance for patient-administered anticancer medications (including oral and self-injected drugs) than for intravenously or provider-injected anticancer medications, regardless of drug formulation or benefit category.

• Applies to all health benefit plans issued or delivered in Alabama, including HMOs, PPOs, and similar entities, but excludes accident-only, dental-only, Medicare supplement, workers' compensation, and other limited benefit policies.

• Prevents health plans from circumventing this requirement by increasing cost-sharing for intravenous or injected chemotherapy drugs or by reclassifying anticancer medication benefits.

• Becomes effective on the first day of the third month following passage and approval by the Governor.